Krebs Biochemicals submits SEBI Reg 74(5) certificate for Q1FY27
Krebs Biochemicals & Industries Limited submitted its SEBI Regulation 74(5) certificate for the quarter ended June 30, 2026. The certificate confirms dematerialization/rematerialization details were provided to stock exchanges by the Registrar & Share Transfer Agent, KFIN Technologies Limited.
This is a standard regulatory compliance filing, which is a routine activity for listed companies and is unlikely to have a material impact on the company's stock or operations.
The announcement is a routine compliance filing and does not contain any new financial information or significant business updates that would sway the sentiment.
Krebs Biochemicals and Industries Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate was received from KFIN Technologies Limited, the company's Registrar and Share Transfer Agent.
This certificate confirms that the details of securities dematerialized or rematerialized during the quarter have been furnished to all stock exchanges where the company's shares are listed. The submission is in compliance with the SEBI regulations.
KFIN Technologies Limited, acting as the Registrar to the Issue and Share Transfer Agent for Krebs Biochemicals & Industries Limited, has provided the necessary documentation to NSDL and CDSL, as well as to the stock exchanges. The company secretary and compliance officer of Krebs Biochemicals, Rakesh R Kalbate, has formally submitted this information for the records.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.